Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease

por Guja, Cristian, Frías, Juan P., Suchower, Lisa, Hardy, Elise, Marr, Galina, Sjöström, C. David, Jabbour, Serge A.
Publicado 2020

Correction to: Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease

por Guja, Cristian, Frías, Juan P., Suchower, Lisa, Hardy, Elise, Marr, Galina, Sjöström, C. David, Jabbour, Serge A.
Publicado 2020

Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week r...

por Frías, Juan P., Maaske, Jill, Suchower, Lisa, Johansson, Lars, Hockings, Paul D., Iqbal, Nayyar, Wilding, John P. H.
Publicado 2021

Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials

por van der Aart ‐ van der Beek, Annemarie B., van Raalte, Daniel H., Guja, Cristian, Hoogenberg, Klaas, Suchower, Lisa J., Hardy, Elise, Sjöström, C. David, Heerspink, Hiddo J.L.
Publicado 2020